Isis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Harvard College

Genzyme Corporation

Diane Tribble

Susan M Freier

Mark J Graham

Sanjay Bhanot

Rosanne M Crooke

Andrew T Watt

Kristina M Lemonidis

Kristina L Lemonidis

Richard S Geary

Zhengrong Yu

Mark K Wedel

Frank M Sacks

Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

Methods for treating hypercholesterolemia

Methods for long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated ApoB are provided.

Administering antisense oligonucleotides complementary to human apolipoprotein B

Disclosed herein are compositions and methods for lowering Apolipoprotein C-III (ApoC-III) in a subject in need thereof. Subjects in need of ApoC-III reduction include subjects with elevated ApoC-III levels, subjects with a condition associated with ApoC-III, subjects with diabetes, obese subjects and subjects with cardiovascular disease. Compositions to lower ApoC-III include compounds targeting Apolipoprotein B (ApoB) such as Mipomersen and other antisense compound targeting ApoB.

Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III

Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating hypercholesterolemia, or alternatively for treating or preventing atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

Growing community of inventors

Carlsbad, CA, United States of America

Diane Tribble